Valeant Pharmaceuticals International, Inc. (VRX,VRX.TO) announced it has decided to list SILIQ (brodalumab) injection, at $3,500 per month, which is the lowest injectable biologic psoriasis treatment currently on the market. SILIQ will also be included in the company's patient access program. The sales and marketing are expected to commence in the U.S. during the second half of 2017.
SILIQ, a monoclonal antibody that targets the IL-17 receptor for patients with moderate-to-severe plaque psoriasis, is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org